X
12Jan

Sanofi to Acquire Kymab for up to $1.45 Billion

Goodwin | | Return|
Sanofi announced that it has entered into an agreement to acquire Kymab, a clinical-stage biopharmaceutical company developing fully human monoclonal antibodies with a focus on immune-mediated diseases and immuno-oncology therapeutics, for an upfront payment of approximately $1.1 billion and up to $350 million upon achievement of certain milestones.  The acquisition will give Sanofi full global rights to Kymab’s KY1005, which binds to OX40-Ligand and has the potential to treat a wide variety of...
By: Goodwin
Source Url: https://www.jdsupra.com/legalnews/sanofi-to-acquire-kymab-for-up-to-1-45-2569030/

Related

Delaware Chancery Court Holds That a Transaction Involving a Conflicted Board Majority Can Be Cleansed If Appropriate Safeguards Are Implemented

In a legal challenge to a corporate transaction, the applicable standard of review is often outcome ...

Read More >

Arkansas' Social Media Statute: What It Tells Us, What It Doesn't

In August 2013, Arkansas enacted a statute intended to regulate employers’ ability to access social...

Read More >

“No Good Deed Goes Unpunished” – The Consequences of Attendance and Point Reduction Policies for Employers - Labor & Employment Newsletter

In most industries, it is common for employers to implement no-fault attendance policies to discipli...

Read More >

Breathing Room? California Legislature Passes Two Major Amendments to California Consumer Privacy Act (CCPA)

Businesses may receive a bit of breathing room as a result of two amendments to the California Consu...

Read More >

A New Look At The Doctor Deposition

In the context of the practice of medicine, we are all very familiar with the Latin phrase primum es...

Read More >

Blog: Social Distancing From a (Supposed) Life Partner: Early Lessons From Deals Terminated and On the Rocks in the COVID-19 Era

In “La La Land,” Damien Chazelle’s Oscar winning film, the audience thinks it has a formulaic Hol...

Read More >